Postmenopausal Osteoporosis — The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam
Citation(s)
The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam, a Cytochrome P450 3A4/P-gp (CYP3A4) Substrate, in Postmenopausal Osteoporotic Women